Home / News / Certara Shanghai relocates to a new location and sets sail for a new era

Certara Shanghai relocates to a new location and sets sail for a new era

Certara Shanghai relocated the office and held a grand opening ceremony at Hong Kong Plaza in Huangpu District, Shanghai on September 9, 2022. The goal of this move was to provide greater support to local customers  and facilitate meeting market needs. Customers and key opinion leaders in China were invited to the ceremony where they shared the latest trends in drug discovery and clinical pharmacology.

Strengthening a partnership with customers in China for innovative drug development

The ceremony started with sharing a cerebration video featuring  Certara’s global leaders. “We are thrilled to be opening Certara’s new office in China.” said William F. Feehery, Ph.D., CEO of Certara. “We are excited to expand with this new location to strengthen our partnership with customers in the rapidly growing and innovative Chinese pharmaceutical industry.”

“China is a huge growth engine for medical research and for the discovery and development of life changing medicines.” said Drayton Virkler, Managing Director of Certara Shanghai. “We are excited to bring our innovative approaches to China through our software platforms and our service offerings to help accelerate medicines for China and the world.”

Certara’s China team is ready to support local biopharmaceutical companies

Certara Shanghai currently has six local experts in software and consulting service divisions. They work closely with customers to provide modeling and simulation software as well as clinical pharmacology consulting service. “The biopharmaceutical industry in China is booming.” Gailing Li, Ph.D., Chief Scientific Officer and Senior Vice President of Certara Integrated Drug Development said as she presented her slides. “We believe Certara Shanghai can serve as a community hub for the industry to exchange knowledge and technology and provide more local services to the Chinese biopharmaceutical companies. We would like to support them to accelerate the globalization and modernization of drug development and help cultivate new talent here in China.”